
Broker Upgrades and Downgrades & Key UK Corporate Snapshots 16 February 2016
UK Broker Upgrades / Downgrades Code Company Broker Recomm. From Recomm. To Price From Price To Upgrades ACA Acacia Mining Plc Deutsche Bank Buy Buy 280 290 HSTG
UK Broker Upgrades / Downgrades Code Company Broker Recomm. From Recomm. To Price From Price To Upgrades ACA Acacia Mining Plc Deutsche Bank Buy Buy 280 290 HSTG
Northland Capital partners view: Dosing of first patients always represents a major milestone in phase 3 trials, as it confirms that preparations have gone to plan and that there are
ImmuPharma PLC (LSE:IMM),, the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor(TM), its lead
The board of Golden Saint (AIM: GSR) is pleased to announce that that on 12 February 2016 the Company raised £150,000 by the issue of 500,000,000 new Ordinary Shares of
Share Tips, Bids and Rumours Shire calls halt to $50 billion acquisition spree: Shire has called a halt to the $50 billion acquisition spree that has transformed the London-listed drugmaker
Share Tips, Bids and Rumours Lebedevs in talks over £24 million i sale: Alexander and Evgeny Lebedev are set to sell the i newspaper for about £24 million in cash,
The Times Oil ‘will struggle to hit $50 again’: Oil prices may not recover to more than $50 a barrel and could be set for further steep falls before they
Beaufort Securities view on Advanced Oncotherapy: Yesterday’s agreement with Thales tells investors two things: (i) That the signing of an agreement with such a highly prestigious global operator, that generally
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, has told DirectorsTalk that it has entered into an industrialisation agreement with Thales, for its proprietary LIGHT
The Times Bank builds $98 billion Brexit war chest to save pound: Britain’s war chest for emergencies has risen by $25 billion over the past year to protect against market